Scale Theranostics
from Pilot to Payer

The most significant barrier occurs at the regulatory-to-market access transition, where approximately 70% of companies experience stalls or failure. This bottleneck stems from the unique complexity of theranostic solutions, which must navigate both pharmaceutical regulatory pathways and medical device/AI software requirements simultaneously.

​

Top Commercialization Barriers

Top Commercialization Barriers in Precision Theranostics (2025)

 

% of Companies Reporting Each Barrier:

• Reimbursement Uncertainty – 67%

  • Most critical barrier to launch and scale

  • Only 33% of AI-enabled diagnostics secure reimbursement in year one

  • Delays lead to cash flow issues and restricted growth

​​

• Clinical Adoption – 58%

  • HCP resistance due to:

    • Complex AI/ML integration into workflows

    • "Black box" concerns around AI decision-making

    • Training gaps and workflow disruption

​​

• Regulatory Navigation – 52%

  • Dual compliance with:

    • FDA’s evolving SaMD guidelines

    • Traditional radiopharmaceutical and diagnostic approvals

  • Creates uncertainty and delays in submission strategies

​​

How Strategic Growth AI Solves These Challenges

​

1. Comprehensive Scaling Solutions

• Commercial Growth Sprints

  • Short, focused interventions (4–8 weeks)

  • Drive payer engagement, provider expansion, and market access

  • Custom-built for theranostics—no generic playbooks

• Fractional Market Expansion Teams

  • On-demand access, market access, sales, and KOL specialists

  • No full-time hiring risk, ideal for capital-constrained companies

  • Expertise when and where it's needed most

• RWE & Adoption Amplification

  • Turn real-world results into persuasive proof points

  • Deploy success stories to expand influence and win market share

  • Build commercial credibility through operational validation

• Payer Uplift & Channel Enablement

  • Improve pricing models and reimbursement strategy

  • Support CPT coding, DRG optimization, and value-based models

  • Unlock new revenue via outpatient, specialty, and hospital channels

 

2. Technology-Enabled Market Intelligence

• Clarity AI™ Platform

  • Predictive analytics tailored to theranostics

  • Maps:

    • Facility nuclear imaging volumes

    • Reimbursement trends

    • KOL and referral network dynamics

  • Identifies high-probability expansion targets

  • Outputs real-time hospital scoring and influence mapping

​​

Strategic Growth AI = Execution + Insight

• We’re not just advisors, we plug in and drive execution

• Our AI-powered tools and commercialization sprints are built to overcome systemic barriers

• With SGAI, theranostic companies don’t just launch—they scale with speed and confidence

 

 

Competitive Analysis

​

Market Positioning

​

Strategic Growth AI Competitive Advantage:

 

Winning in Theranostics Commercialization

​

Strategic Growth AI (SGAI) bridges the critical gap between clinical pilot and scaled commercial success for AI-enabled theranostics. We combine deep domain knowledge in AI, nuclear medicine, and commercialization with fast, modular execution.

 

Where Others Fall Short

​

Competitor Type

 

1. Big 4:

Strength: Regulatory & payer scale

Weakness: High cost, slow execution, generic models not suited for AI theranostics

 

2. Traditional CROs:

Strengths: Clinical trials, KOL engagement

Weak in AI workflows, market access, and post-approval commercialization

 

3. PR/Boutique Firms

Strengths: Branding & thought leadership

Weakness: No regulatory or payer expertise

 

4. In-House SME Teams

Strength: Strong tech/product knowledge

Weakness: Lack bandwidth for launch, payer, and HCP rollout

​

Why Strategic Growth AI Wins

 

In Precision Theranostics Expertise

 

We deliver where it matters most:

• AI, commercial, regulatory and clinical strategy

• Companion diagnostic and value-based reimbursement readiness

 

Modular, Fast, Capital-Efficient

• No bloated retainers

• Sprints executed in 4–8 week windows

• Built to meet SME and spinout constraints

• Cross-functional experts: market access, regulatory, KOL, AI/ML

 

Launch Track Record

• Launch timelines reduced by up to 40%, and your venture de-risked by up to 60%

• Results delivered in Canada, U.S.

• AI-powered Clarity AI™ for commercial and regulatory insight

​​

How We Work

​

1. Diagnostic Sprint

Pinpoint bottlenecks, map opportunities, and define action plans using our Clarity AI™ platform

​

2. Modular Execution Sprints

Each sprint targets high-value outcomes:

• Market Access: Payer strategy & reimbursement

• KOL Activation: Engagement & education tools

• RWE Generation: Study design & data protocols

• Regulatory Readiness: FDA/Health Canada pathways

 

3. Continuous Optimization
With analytics access we track adoption, payer wins, physician use, and revenue growth, refining strategy as we go.

 

Positioned for the Future

• Regulatory Agility: We navigate AI/ML & radiopharma evolving frameworks (e.g., FDA SaMD, international harmonization).

• Tech Convergence: We integrate AI, diagnostics, and therapeutics into compliant, scalable solutions.

• Precision Reimbursement: We prepare you for value-based models where outcomes—not access—drive revenue.

 

Why Strategic Growth AI?

 

• Accelerated Commercialization: Launch timelines cut up to 40%.

​​

• Integrated Expertise: Regulatory, reimbursement, GTM, and data analytics in one program

​​

• AI-Driven Insight: Real-time hospital scoring and referral-pattern models competitors lack

​​

• Global Perspective: Hands-on success across North America, EU, and APAC

​​

• Seamless Scale-Up Support: Embedded specialists fill skills gaps while your team grows

​​

Let’s discuss how to launch smarter, faster, and with less risk.